Nortriptyline

Generic Name: Nortriptyline

Brand Names: Aventyl, Pamelor

Drug Type: Small Molecule

Chemical Formula: C_₁₉H_₂₁N

CAS Number: 72-69-5

Unique Ingredient Identifier: BL03SY4LXB

Background: Nortriptyline hydrochloride, the active metabolite of amitriptyline, is a tricyclic antidepressant (TCA). It is used in the treatment of major depression and is also used off-label for chronic pain and other conditions.

Indication: Nortriptyline is indicated for the relief of the symptoms of major depressive disorder (MDD). Some off-label uses for this drug include treatment of chronic pain, myofascial pain, neuralgia, and irritable bowel syndrome.

Associated Conditions: Chronic Pain, Irritable Bowel Syndrome (IBS), Major Depressive Disorder (MDD), Myofascial Pain Syndrome, Pain, Orofacial, Postherpetic Neuralgia

Associated Therapies: -

Clinical Trials

Interpersonal Psychotherapy for Treatment Resistant Depression

First Posted Date: 2013-07-11

Last Posted Date: 2013-07-11

Lead Sponsor: Hospital de Clinicas de Porto Alegre

Target Recruit Count: 74

Registration Number: NCT01896349

Locations: 🇧🇷
Federal University of Rio Grande do Sul / Hospital de Clínicas de Porto Alegre (HCPA), Porto Alegre, RS, Brazil

Effect of Doxepin and Nortriptyline on Irritable Bowel Syndrome

Phase 2

Completed

Conditions: Irritable Bowel Syndrome

Interventions: Drug: Doxepin
Drug: placebo
Drug: Nortriptyline

First Posted Date: 2010-12-31

Last Posted Date: 2010-12-31

Lead Sponsor: Qom University of Medical Sciences

Registration Number: NCT01268709

Locations: 🇮🇷
Gastrointestinal Research center,Beheshti Hospital, Qom, Iran, Islamic Republic of

Effect of Nortriptyline in Cortical Representation of Heartburn in Nonerosive Reflux Disease (NERD) Patients

Phase 3

Completed

Conditions: Gastroesophageal Reflux Disease

Interventions: Drug: Nortriptyline
Drug: Placebo arm

First Posted Date: 2010-02-09

Last Posted Date: 2012-07-17

Lead Sponsor: Universidade de Passo Fundo

Target Recruit Count: 20

Registration Number: NCT01065649

Locations: 🇧🇷
Kozma, Passo Fundo, RS, Brazil

A Single-Center Exploratory Study to Assess the Activity of CRx-197-002 in Plaque Psoriasis

Phase 2

Completed

Conditions: Plaque Psoriasis

Interventions: Drug: CRx-197
Drug: Nortriptyline
Other: Placebo
Drug: Calcipotriol

First Posted Date: 2008-11-24

Last Posted Date: 2009-01-15

Lead Sponsor: Zalicus

Target Recruit Count: 20

Registration Number: NCT00796211

Locations: 🇩🇪
ProInnovera, Muenster, Germany

A Phase I Study to Assess the Safety and Tolerability of Topical CRx-197 Formulations in Healthy Volunteers

Phase 1

Completed

Conditions: Atopic Dermatitis

Interventions: Drug: nortriptyline HCl + loratadine
Drug: nortriptyline HCl
Drug: Active ingredient free vehicle cream of CRx-197
Drug: mometasone furoate

First Posted Date: 2008-07-24

Last Posted Date: 2008-09-26

Lead Sponsor: Zalicus

Target Recruit Count: 20

Registration Number: NCT00721331

Locations: 🇩🇪
PROINNOVERA GmbH, Muenster, Germany

Relapse Prevention With Escitalopram or Nortriptyline Following Electro-Convulsive Treatment (DUAG-7)

Phase 4

Terminated

Conditions: Major Depression

Interventions: Drug: escitalopram
Drug: nortriptyline

First Posted Date: 2008-04-17

Last Posted Date: 2014-12-09

Lead Sponsor: Hillerod Hospital, Denmark

Target Recruit Count: 47

Registration Number: NCT00660062

Locations: 🇩🇰
Mental Health Centre Copenhagen Department O, Copenhagenl, Denmark

Study of CRx-191 to Assess Activity in Plaque Psoriasis

Phase 2

Completed

Conditions: Plaque Psoriasis

Interventions: Drug: Vehicle (placebo)
Drug: mometasone furoate
Drug: nortriptyline HCl

First Posted Date: 2007-11-14

Last Posted Date: 2008-09-25

Lead Sponsor: Zalicus

Target Recruit Count: 20

Registration Number: NCT00557739

Locations: 🇩🇪
bioskin GmbH, Berlin, Germany

Effect of Nortriptyline on Abdominal Pain/Discomfort and Quality of Life in Patients With Nonulcer Dyspepsia

Not Applicable

Terminated

Conditions: Non Ulcer Dyspepsia

Interventions: Drug: Placebo
Drug: Nortriptyline

First Posted Date: 2007-10-23

Last Posted Date: 2017-05-17

Lead Sponsor: The Cleveland Clinic

Target Recruit Count: 5

Registration Number: NCT00547703

Locations: 🇺🇸
Cleveland Clinic Florida, Weston, Florida, United States

Phase I Study of Topical CRx-191 in Normal Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: CRx-191
Drug: mometasone furoate
Drug: nortriptyline HCl
Drug: Karison® Creme
Drug: Vehicle

First Posted Date: 2007-10-16

Last Posted Date: 2007-11-15

Lead Sponsor: Zalicus

Target Recruit Count: 20

Registration Number: NCT00544687

Locations: 🇩🇪
bioskin GmbH, Hamburg, Germany

Treatment of Depression in Parkinson's Disease Trial

Phase 2

Completed

Conditions: Parkinson Disease
Depression

Interventions: Other: placebo
Drug: paroxetine
Drug: Nortriptyline

First Posted Date: 2003-06-13

Last Posted Date: 2015-11-24

Lead Sponsor: Rutgers, The State University of New Jersey

Target Recruit Count: 52

Registration Number: NCT00062738

Locations: 🇺🇸
Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy